PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire•14/08/2026•08:00 ET
0
Whiz Insights
* Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed
* Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027
Get started
Create a free account to read the full story.